Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
DDW Editor Reece Armstrong sits down with Tarek Samad, Lundbeck’s Senior Vice President and Head of Research to discuss AI and supercomputing within the drug discovery industry following the company’s recent agreement with the Danish Centre for AI Innovation (DCAI). In May this year, Lundbeck announced an agreement with the… Read More
A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284. Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, has published a study in Cell, introducing its optogenetic screening platform. According to the paper, the platform allows for precise and dynamic control of biological targets and processes, unlocking a powerful new… Read More
Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies. Organisations that move quickly… Read More
The DDW Summer issue is available to read now. It features in-depth articles on the technologies and advancements driving genomics drug discovery, how supercomputing can drive neuroscience discoveries, and everything you need to know about spatial biology. Other features include: A market report on… Read More
Biotech Cellarity has dosed its first patient in a Phase I clinical trial of CLY-124, a first-in-class Globin-Switching oral medicine designed to treat sickle cell disease (SCD). “Initiation of our first-in-human clinical study for CLY-124 represents the delivery of our first clinical asset from our platform with… Read More
OutSee has secured £1.8 ($2.4) million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the company’s in-house target discovery programme… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise… Read More
Discover how the Agilent BioTek Cytation cell imaging multimode reader and ViQi’s AVIA provide a powerful, integrated solution for viral infectivity analysis. Download the application note to explore how this innovative approach offers key advantages over traditional assays, including: High-throughput, cost-effective analysis: AVIA minimises reagent use, incubation time, and replicate needs,… Read More
News round-up for 23-27 June by DDW Senior Digital Content Editor Diana Spencer. As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise the importance of advanced technologies to the success of drug discovery, including digital control arms for clinical studies, nanobody-based… Read More
Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has collaborated with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used… Read More
Hosted by Drug Discovery World and sponsored by Benchling, this free webinar will explore the impact of AI on drug discovery innovation. The webinar will see AI experts and leaders discuss where innovation is occurring and what the challenges are to overcome in drug discovery and development. You will… Read More
